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AneurysmAbstract Background: Cerebral vasospasm (CVS) is a disabling disease with high morbidity and
mortality risk. Milrinone (phosphodiesterase III inhibitor) has inotropic and vasodilator effects,
noninvasive transcranial cerebral oximetry (rSO2%) useful in estimating the effect of triple-H ther-
apy preventive measures against CVS.
Objective: The objective of the study is to clarify the value of the use of Milrinone continuous IV
infusion as a cerebral vasodilator in post-clipping spasm prevention during the period of maximum
vasospasm incidence, guided by noninvasive rSO2%.
Methods: Post-clipping all patients extubated in the operative room, shifted to Neurosurgical ICU,
and fully monitored. Then, in the period from 4th till the 11th day post-clipping, they were divided
into two groups 15 patients each: Group 1: control group, given Norepinephrine continuous IV
infusion alone in a dose ranges from 0.05 to 0.2 lg/kg/min. Group 2: given Norepinephrine contin-
uous IV infusion 0.05–0.2 lg/kg/min, Plus Milrinone starting with 50 lg/kg bolus dose, followed by
IV infusion at a rate of [0.5–0.75 lg/kg/min]. IMAP, ICP and CPP, GCS, Norepinephrine dose,
rSO2%, were recorded every 6 h for the next 168 h. Any attack of cerebral vascular spasm recorded
as number and % in each group as an incident.
Results: MBP, rSO2%, ICP, CPP, Norepinephrine Infusion dose, and GCS were signiﬁcantly
increased in Group (2) in comparison with Group (1) mostly during the period of the study. CVS
74 M.A. Ghanem, A.M. Shabanaoccurrence was signiﬁcantly lower in group (2), i.e., (20%) cases compared to (46.6%) in group (1).
Conclusions: Milrinone improved signiﬁcantly the global cerebral oxygenation and reduced the inci-
dence of cerebral vasospasm during the dangerous period of cerebral spasm after cerebral aneurysm
clipping.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Cerebral vasospasm (CVS) secondary to aneurysm induced sub-
arachnoid hemorrhage (SAH) is a disabling disease with high
risks of morbidity and mortality even after successful surgical
clipping. CVS is themost common cause of delayed neurological
deﬁcit affecting up to 30% of patients who survive the initial
hemorrhage, current therapy for prevention and treatment of
symptomatic vasospasm includes hypertensive, hypervolemic
hemodilution (triple-H therapy), calcium channel antagonists,
and early surgery with clot removal. [1] The clinical CVS syn-
drome starts with an inclination to sleep, confusion, and stupor.
Normally, the symptoms appear between the 5th to the 7th day
of an SAH and rarely occur after 2 weeks. The pathophysiology
of vasospasm is not totally understood [2].
Milrinone, a phosphodiesterase III inhibitor that affects
CAMP pathways producing both inotropic and vasodilator ef-
fects, also was ﬁrst used in the treatment of CVS after rupture
of intracranial aneurysm in 2001 [3]. Constantoyannis and his
colleagues 2007 [4] documented that noninvasive transcranial
cerebral oximetry may be useful in estimating the clinical im-
pact of triple-H therapy as a preventive measures against arte-
rial CVS in aneurysm induced SAH patients.
Antoine and his colleagues 2012 [5] recommended that
there is great need for more clinical studies on standardized
intravenous and/or intra-arterial administration protocols en-
abling comparison between drugs (i.e., Milrinone vs. Norepi-
nephrine). On this future vision, the aim of this study was to
clarify the value of the use of Milrinone continuous IV infu-
sion as a cerebral vasodilator in post-clipping spasm preven-
tion during the period of maximum vasospasm incidence
(between the 4th and the 11th day post-clipping) in the neuro-
surgical ICU, guided by noninvasive transcranial cerebral
mixed venous oxygen saturation (rSO2). All patients must
have continuous normovolemic state simultaneously with suf-
ﬁcient cerebral perfusion level utilizing Norepinephrine that
provides safe supporting effective systemic hypertension.
1.1. Patient and methods
After protocol approval by local ethics committee, written in-
formed consent was taken from each patient or relatives. In
this present study, patients were selected depending on a merge
of clinical and radiological grading and classiﬁcation, respec-
tively; 1st clinical grade patients were selected of grade 1 or
2, or 3 according to world federation of neurosurgeon grading
scale, [22] shown in Table 6, and 2nd by radiological classiﬁca-
tion using modiﬁed Fissure classiﬁcation only class 2, 3, and 4
only if associated with good clinical grading 1, 2, or 3 world
federation grades. (Fissure classiﬁcation was modiﬁed by Cla-
assen and coworkers classiﬁes the appearance of subarachnoid
hemorrhage on CT scan and reﬂects the additive risk from
SAH size and associated with intraventricular hemorrhage asfollowing: 0 – none; 1 – minimal SAH without IVH; 2 – min-
imal SAH with IVH; 3 – thick SAH without IVH; 4 – thick
SAH with IVH) [23]. In this present study, Patients were di-
vided in two groups each 15 patients, all patients, aged from
25 to 60 years old, of either male or female.
Exclusion criteria: Evident vasospasm with trans-cranial
Doppler or CT angiography, peripheral vascular disease, pre-
operative cognitive dysfunction, neuromuscular, primary car-
diac, pulmonary, hepatic, renal and endocrine disorders,
Glasgow Coma Scale GCS 6 12, preoperative ventilatory or
circulatory (pharmacological and mechanical) support, pul-
monary edema, also aneurismal rebleeding after surgical clip-
ping patients, maintaining endotracheal intubation, delayed
recovery after surgical clipping, and obese.
In this study, hypothesis was that addition of continuous IV
infusion Milrinone to IV infusion norepinephrine after clip-
ping of cerebral aneurysms (during the period of maximum
cerebral arterial spasm incidence) will improve rSO2.
The primary outcome: Changes in rSO2 (each 6 h for post-
clipping for 168 h = 1 week).
The secondary outcome: measurement of mean arterial
blood pressure, cerebral perfusion pressure, intracranial pres-
sure, doses of norepinephrine, conscious level GCS (each 6 h
for post-clipping 168 h = 1 week) and organ functions once/
day for 7 successive days (Serum ALT, serum AST, Serum bil-
irubin, Serum albumen, Serum Cr, and serum urea).
Group patients sample size: A pilot study showed that the
normally distributed mean transcutaneous cerebral mixed oxy-
gen saturation (rSO2) after start of norepinephrine infusion dur-
ing the postoperative period after aneurismal clipping was 61%
(SDof 10), with type I error of 0.05 and a power of 90%.Apriori
power study indicated a sample size of 15 patients for each group
was sufﬁciently large to detect a 20% differences in the mean
rSO2 after the start of norepinephrine infusion.
Anesthesia during surgery: (All aneurysms were clipped
within 24 h of the onset of SAH) was induced with Fentanyl
1 lg/kg, then lidocaine 1 mg/kg, then Propofol 2 mg/kg, and
ETT facilitated using 0.1 mg/kg Cisatracurum then maintained
with total intravenous anesthesia of continuous IV infusion
drugs [Remifentanil 0.05–2 lg/kg/min, Propofol 50–200 lg/
kg/min, and muscle relaxant Cisatracurum infusion of
0.1 mg/kg/h]. After surgical clipping, an open and surgically
functioning external ventricular devise catheter (EVD) [6]
was then connected to the pressure transducer ﬁxed 1 cm
above the level of temporomandebular joint via which the
intracranial pressure (ICP) will be recorded and then cerebral
perfusion pressure (CPP) was calculated (utilizing the famous
equation CPP = mean arterial blood pressure MBP-ICP) [7].
Post-surgical clipping extubation just after operation in the
operative room, conscious and spontaneously breathing, pro-
tocol criteria for extubation on table after clipping; fully con-
scious and oriented, GCS > 13, Obey commands, no new
motor deﬁcits, noncomplicated surgery, stable vitals,
temp. > 36 C, FiO2 < 0.5, PEEP 6 5 cm H2O, Pa/FiO2 ra-
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Chart 1 Transcranial Noninvasive O2 saturation of the studied groups in% related to time in hours.
Effects of Milrinone continuous intravenous infusion on global cerebral oxygenation and cerebral vasospasm 75tio > 300, PaO2 > 60 mmHg, PaCO2 35–45 mmHg,
pH > 7.3, TOF > 0.9, VTe > 5 ml/kg, UOP > 0.5 and
<3 ml/kg.
Then, patients shifted directly to the Neurosurgical ICU
and connected to full monitoring system including HR, ECG
leads, arterial oximetry probe, invasive arterial blood pressure
via pre-inserted arterial 18 gage cannula, CVP monitoring, and
the transcutaneous cerebral mixed oxygen saturation forehead
bilateral interconnected adhesive probes (CASMED-FORE-S.
GHT noninvasive cerebral oximetry monitoring devise).
Then, for all patients: 1-Both groups 1 and 2 were kept nor-
movolemic utilizing the isotonic normal saline 0.9% solution
rates between 80 and 100 cc/h (Mayer and his colleagues
2005) [8] as a basic hourly infusion solution. The goal is to
maintain the patient normovolemic by keeping the central ve-
nous pressure (CVP) 5–8 mmHg in the patient recovering from
a SAH with normal hourly urine output for all patients of the
study.
2-Both groups 1 and 2 started Norepinephrine (levofed)
vasopressor infusion support in an IV infusion dose ranges
from 0.05 to 0.2 lg/kg/min [effective doses of norepinephrine
were deﬁned as doses required to increase mean arterial pres-
sure (MAP) by 20 mmHg] [9]. MAP was maintained at be-
tween 100 and 120 mmHg targeting CPP (MAP-ICP)
>80 mmHg.
Then, after passage of 96 h (4 days) (as the 5th day is the
start of the period of highest incidence of cerebral vasospasm
after cerebral aneurismal clipping) [2] postoperatively in the
neurosurgical ICU, patients were divided into two groups 15
patients in each group as follow:
Group 1 = Norepinephrine alone group (Control group):
Norepinephrine continuous infusion alone in a dose range
0.05–0.2 lg/kg/min to keep MAP between 100 and 120 mmHg
targeting CPP (MAP-ICP) >80 mmHg .
Group 2 = Norepinephrine plus Milrinone (Milrinone
group): Norepinephrine continuous infusion in a dose range
0.05–0.2 lg/kg/min to keep MAP between 100 and 120 mmHg.
targeting CPP (MAP-ICP) >80 mmHg, Plus Milrinone (cere-
bral arterial vasodilator and +ve inotropic) starting with
50 lg/kg bolus dose [4], followed by intravenous infusion at
a rate of [0.5–0.75 lg/kg/min] [3], according to the rSO2%
monitoring starting by 0.5 lg/kg/min and increase up to
0.75 lg/kg/min if rSO2% dropped under 60%.Data recording of GCS, norepinephrine infusion dose,
rSO2%, IMAP, ICP and CPP calculated (MAP-ICP), all were
recorded every 6 h for the next seven successive postoperative
days = 168 h. Organ functions (Serum ALT, serum AST, Ser-
um bilirubin, Serum albumen, Serum Cr, and serum urea) the
once daily measurement (for seven successive days).
Any attack of cerebral vascular spasm (CT angiographic-
proven arterial diameter reduction >40%) [10]), these cases
will be recorded as number and % in each group as an incident
and soon start the management of cerebral arterial spasm in the
form of oral or via nasogastric tube 60 mg Nimodipine every
4 h and continued for up to 21 day, Hetastarch (6%) 500 ml bo-
lus infusion added to the basic hourly 0.9% normal saline ﬂuid
infusion to maintain the central venous pressure CVP of 8–
10 mmHg (during spasm as a treatment). Simultaneously, mil-
rinone 50 lg/kg bolus then intravenous infusion of a higher rate
than prevention rate already used in this study [0.75–1.25 lg/
kg/min] then gradually reduce the dose according to the
rSO2% monitoring down to a rate of 0.75 lg/kg/min if
rSO2% improves over 70%, plus Norepinephrine infusion rate
up to[ 0.2 lg/kg/min] to maintain invasive MAP between 100
and 130 mmHg, targeting CPP (MAP-ICP) > 80 mmHg .2. Statistical analysis
Data of the study were collected and entered into computer.
Statistical analysis was done by using statistical package for
social science version 16 (SPSS). The data were normally dis-
tributed by using Kolmogrov–smirnov test. The data were pre-
sented in the form of mean and standard deviation. Student’s
t-test was used to compare between quantitative data of two
groups. Signiﬁcance was considered at p value less than 0.05.
According to the pilot study done before this study to de-
tect the sufﬁcient number of patients of each group of the
study showed that the normally distributed mean rSO2 after
start of norepinephrine infusion during the postoperative per-
iod after aneurismal clipping was 61% (SD of 10). A prior
power study indicated a sample size of 15 patients for each
group was sufﬁciently large to detect a 20% differences in
the mean rSO2 after the start of norepinephrine infusion, with
type I error of 0.05 and a power of 90%. We added 10% more
to compensate for the dropped out cases.
Table 1 Transcranial noninvasive O2 saturation and mean arterial blood pressure of the studied groups.
Group Time
6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h 54 h 60 h 66 h 72 h 78 h 84 h
Cereb. Transcr. Noninvv. O2 saturation
Group1 Mean ± SD 66.33 ± 1.71 64.20 ± 5.72 66.13 ± 3.20 67.80 ± 1.37 68.33 ± 2.58 67.93 ± 1.03 66.40 ± 1.54 65.73 ± 4.13 65.46±.51 66.06 ± 1.03 66.40 ± 1.54 64.33 ± 2.58 66.40 ± 1.54 67.53 ± 2.87
Group2 Mean ± SD 66.60 ± 2.64 67.80 ± 3.34 69.73 ± 1.71 70.60 ± 3.48 72.66 ± 2.35 73.80 ± 1.26 75.40 ± 1.59 74.53 ± 1.50 75.13 ± 2.38 76.13±.99 75.33 ± 2.52 77.0 ± 2.26 75.86 ± 1.64 76.20 ± 1.61
T test .32 2.10 3.83 2.89 4.80 13.91 15.67 7.75 15.33 27.24 11.67 14.27 16.24 10.18
P value .74 \ \ \ \ \ \ \ \ \ \ \ \ \
Mean Arterial Blood Pressure
Group1 Mean ± SD 105.53 ± 0.83 106.47 ± 1.30 106.33 ± 1.23 106.20 ± 1.37 106.33 ± 1.23 106.47 ± 1.30 106.33 ± 1.23 106.93 ± 2.01 106.87 ± 2.0 106.40 ± 1.54 106.93 ± 2.01 106.00 ± 2.00 106.07 ± 1.03 1.0647 ± 1.6
Group2 Mean ± SD 108.40 ± 1.24 110.47 ± 1.64 112.00 ± 2.82 113.27 ± 1.57 112.87 ± 3.06 113.73 ± 2.73 113.80 ± 3.16 114.47 ± 2.89 114.60 ± 2.19 115.40 ± 1.18 115.33 ± .89 115.73 ± 1.03 115.33 ± 1.11 114.33 ± 2.05
T test 7.42 7.39 7.11 13.07 7.65 9.28 8.50 8.26 9.93 17.88 14.73 16.74 23.64 11.57
P value \ \ \ \ \ \ \ \ \ \ \ \ \ \
Time
90 h 96 h 102 h 108 h 114 h 120 h 126 h 132 h 138 h 144 h 150 h 156 h 162 h 168 h
Cereb. Transcr. Noninvv. O2 saturation
Group1 Mean ± SD 68.33 ± .48 68.66 ± 2.43 68.20 ± 2.11 68.53 ± 2.23 68.0 ± 0.00 70.40 ± 2.22 68.40 ± .50 70.60 ± .50 68.60 ± .50 72.000 ± 0.00 68.60 ± .50 70.40 ± .50 68.40 ± .50 72.00 ± .00
Group2 Mean ± SD 76.06 ± 1.53 75.66 ± 3.13 76.40 ± 2.74 76.66 ± 1.75 76.13 ± 2.79 75.73 ± 2.15 76.53 ± 2.55 75.73 ± 1.98 76.26 ± 2.28 75.53 ± 2.74 75.46 ± 1.76 76.20 ± 2.75 77.40 ± 2.61 76.93 ± 1.62
T test 18.6 6.82 9.16 11.08 11.25 6.66 12.07 9.72 12.7 4.98 14.46 8.01 13.09 11.76
P value \ \ \ \ \ \ \ \ \ \ \ \ \ \
Mean Arterial Blood Pressure
Group1 Mean ± SD 106.40 ± 1.54 107.3 ± 0.72 106.33 ± 1.23 106.73 ± 1.70 106.33 ± 1.23 106.33 ± 1.44 115.33 ± 1.04 107.47 ± .51 106.33 ± 2.58 105.93 ± 1.03 106.80 ± 3.09 107.53 ± .51 106.67 ± 2.58 105.93 ± 1.03
Group2 Mean ± SD 114.53 ± 1.12 115.53 ± 1.59 115.47 ± 1.40 115.00 ± 1.13 115.13 ± .990 114.80 ± 1.32 106.33 ± 1.23 114.47 ± 1.18 115.20 ± 1.26 115.40 ± 1.18 114.47 ± 1.30 114.33 ± 2.22 114.20 ± 2.78 114.47 ± 2.89
T test 16.45 18.10 18.89 15.60 21.53 16.73 21.53 20.94 11.94 23.34 8.835 11.52 7.68 10.73
P value \ \ \ \ \ \ \ \ \ \ \ \ \ \
Signiﬁcant increase (\) in cerebral transcranial noninvasive mixed venous O2 saturation (%) in Group 2 in comparison with Group 1: from hour 12 till hour 168 of this study in the Neurosurgical
ICU. Signiﬁcant increase(\) in Invasive Mean Arterial Blood Pressure(mmHg) in Group 2 in comparison with Group 1 from hour 6 till hour 168 of this study in the Neurosurgical ICU.
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Chart 2 Cerebral perfusion pressure of the studied groups in mmHg in relation to time in hours.
Effects of Milrinone continuous intravenous infusion on global cerebral oxygenation and cerebral vasospasm 773. Results
 As regard gender distribution, mean patients age and
weight. There was no signiﬁcant (p< 0.05) difference
between groups (Table 5).
 Global cerebral oxygenation using noninvasive cerebral
mixed venous O2 saturation shown in Table 1 shows signif-
icant increase in Group (2) in comparison with Group (1)
from hour 12 till hour 168 of this study in the NICU.
(Chart 1 clarify the numerical result in a clear graph).
 Invasive Mean Arterial Blood Pressure Table 1 shows signif-
icant increase in Group 2 in comparison with Group 1 from
hour 6 till hour 168 of this study in the Neurosurgical ICU.
 The calculated cerebral perfusion pressure Table 2 shows
signiﬁcant increase in Group 2 in comparison with Group
1 from hour 6 till hour 168 of this study. In the Neurosur-
gical ICU. (Chart 2 clarify the numerical result in a clear
graph).
 Intracranial pressure (ICP) Table 2 shows signiﬁcant increase
in Group 2 in comparison with Group 1 from hour 18 till
hour 168 of this study in the Neurosurgical ICU.
 Glasgow Coma score Table 3 shows signiﬁcant increase in
Group 2 in comparison with Group 1 from hour 6 till hour
168 of this study in the Neurosurgical ICU.
 Norepinephrine Infusion dose Table 3 shows signiﬁcant
increase in Group 2 in comparison with Group 1 from hour
42 till hour 144 of this study in the Neurosurgical ICU.
 As regard organ functions Table 4 shows no signiﬁcant
changes between both groups 1 and 2 as regard Serum
ALT, serum AST, Serum bilirubin, Serum albumen, Serum
Cr, and serum urea during the 7 days of the study.
 As regard cerebral arterial Spasm accidents in each group
was recorded as follows: 3 cases of 15 = (20%) cases in
group 2 (Norepinephrine plus Milrinone group) compared
to 7 cases of 15 = (46.6%) cases in group 1 (Norepineph-
rine alone group).4. Discussion
Noninvasive monitoring of cerebral oxygenation not only used
to determine the underlying regional cerebral parenchymaloxygen saturation (rSO2) utilizing tissue oxygen index (oxyhe-
moglobin divided by the total hemoglobin) but also as an early
detection monitor of hematoma formation. Keeping regional
oxygen saturation greater than 55% is the goal in clinical man-
agement. Baseline number is obtained, and any signiﬁcant
change (reduction of 20% from this deﬁned baseline) is indic-
ative for active management of cerebral hypoxia. Cerebral
oxymetry has numerous problems that have limited its useful-
ness in the Neurosurgical ICU (NICU), and the percentage
distribution of venous, capillary, and arterial blood represent-
ing the cerebral oxymeter signal is undeﬁned [11].
After successful surgical aneurismal clipping, a great chal-
lenge starts in the NICU due to the high incidence of post-clip-
ping critical cerebral arterial spasm (typically occurs within 4–
14 days following hemorrhage in the case of virgin bleeds and
earlier with recurrent hemorrhage, management is by inducing
iatrogenic therapeutic hypertension, hypervolemia, and hemdi-
lution the previously known (triple-H), but according to (Mayer
and his colleagues 2005) [8], it is enough to achieve a normovo-
lemic controlled hypertensive state (CVP of 5 mmHg) for cere-
bral aneurysm spasm prevention, so in this present study, the
aim is to induce therapeutic basal normovolemic controlled
hypertensive state for all patients, then to evaluate the effect
of Milrinone as a cerebral vasodilator on the global cerebral
oxygenation using the noninvasive transcutaneous cerebral
oxymetry.
Milrinone, a phosphodiesterase III inhibitor, affects cAMP
pathways with both inotropic and vasodilator effects. Milri-
none was ﬁrst used in the treatment of cerebral vasospasm
after rupture of intracranial aneurysm in 2001 [3]. According
to (Fraticelli and his colleagues 2008) [12], intra-arterial Milri-
none infused in the cerebral territory is effective and safe for
reversal of cerebral vasospasm after a subarachnoid hemor-
rhage and should be tested in a large randomized trial and still
not widely used as a continuous IV infusion protecting drug
against post-surgical cerebral aneurysm spasm.
In this study, we reported signiﬁcant increase in global cere-
bral oxygenation using noninvasive cerebral mixed venous O2
saturation Group (2) in comparison with Group (1) from hour
12 till hour 168 of this study in the NICU, this could be attrib-
uted to the combined Milrinone cerebral arterial vasodilator
(VD) and the cardiac +ve inotropic effects that leads to sub-
sequent increase in the oxygenated arterial cerebral blood ﬂow
Table 2 Cerebral perfusion pressure and Intracranial pressure of the studied groups.
Group Time
6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h 54 h 60 h 66 h 72 h 78 h 84 h
Cerebral perfusion pressur
Group 1 Mean ± SD 89.4 ± 4.5 85.9±.74 87.3±.79 87.4 ± 1.9 89.5 ± 2.9 88.7 ± 3.7 85.9±.74 87.3±.79 89.1 ± 2.06 86.3 ± 1.98 87.2 ± 0.77 87.3 ± 1.94 89.7 ± 2.76 89.2 ± 3.76
Group 2 Mean ± SD 93.9 ± 1.7 92.9 ± 1.8 95.3 ± 2.54 95.9 ± 2.98 95.1 ± 3.01 96.1 ± 2.25 96.1 ± 2.52 95.3 ± 2.09 96.3 ± 1.43 95.4 ± 1.72 95.9 ± 2.71 95.8 ± 2.93 95.5 ± 2.19 96.0 ± 2.47
T test 3.60 13.62 11.60 9.30 5.23 6.56 15.03 13.94 10.97 13.34 11.99 9.39 6.42 5.84
P value \ \ \ \ \ \ \ \ \ \ \ \ \ \
Intracranial pressure
Group1 Mean ± SD 17.00 ± 1.19 17.00±.92 17.3 ± 0.97 16.7±.70 16.7±.72 16.9 ± 1 .3 17.0 ± 1.36 18.2±.85 17.2±.414 17.8±.93 17.2 ± 1.08 16.5±.639 16.8±.51 17.1 ± 1.09
Group 2 Mean ± SD 17.00±.00 16.9 ± 1.0 16.5±.51 17.3±.72 17.3±.90 18.1±.25 18.2 ± 1.65 17.1 ± 1.00 17.9 ± 1.03 18.6±.81 18.5±.51 18.5±.51 18.4 ± 1.18 18.5 ± 1.18
T test .00 .18 2.80 2.30 2.12 3.50 2.16 3.58 2.55 2.47 4.09 9.42 4.78 3.35
P value 1.000 .854 \ \ \ \ \ \ \ \ \ \ \ \
Time
90 h 96 h 102 h 108 h 114 h 120 h 126 h 132 h 138 h 144 h 150 h 156 h 162 h 168 h
Cerebral perfusion pressur
Group 1 Mean ± SD 88.3 ± 1.95 87.3 ± 1.27 89.1 ± 3.05 90.3 ± 4.33 89.7 ± 4.33 89.1 ± 2.32 86.9 ± 1.03 87.4 ± 1.54 88.0 ± 0.0 89.6 ± 1.54 87.1 ± 1.03 87.6 ± 1.54 88.0 ± 0.0 89.4 ± 1.54
Group 2 Mean ± SD 96.1 ± 2.52 96.3 ± 1.95 95.7 ± 1.23 95.7 ± 2.79 95.2 ± 2.07 95.8 ± 2.93 96.1 ± 1.64 95.7 ± 1.22 96.3 ± 1.23 98.1 ± 2.68 1.00 ± 3.60 1.01 ± 3.22 98.5 ± 1.88 1.00 ± 2.66
T test 9.39 15.04 7.75 4.00 4.45 6.89 18.37 16.35 26.14 10.57 13.91 14.93 21.50 14.39
P value \ \ \ \ \ \ \ \ \ \ \ \ \ \
Intracranial pressure
Group1 Mean ± SD 16.9±.51 17.5±.99 17.2±.414 16.8±.94 17.2 ± 1.08 17.3 ± 1.29 17.0±.65 17.4 ± 1.05 17.3 ± 1.16 17.2 ± 1.20 17.3±.96 17.4±.63 17.1±.91 17.3 ± 1.16
Group 2 Mean ± SD 18.5 ± 1.18 18.8±.41 17.9 ± 1.032 17.6±.82 18.5±.51 18.9 ± 1.55 19.0±.00 18.9 ± 1.03 19.5±.51 19.5±.516 19.0±.00 19.1 ± 1.03 19.5±.516 19.5±.51
T test 4.78 4.57 2.55 2.47 4.09 2.94 11.83 4.02 6.69 6.88 6.98 5.33 8.84 6.69
P value \ \ \ \ \ \ \ \ \ \ \ \ \ \
Signiﬁcant increase (\) in Calculated cerebral perfusion pressure in(mmHg) in Group 2 in comparison with Group 1: from hour 6 till hour 168 of this study in the Neurosurgical ICU. Signiﬁcant
increase (\) in Intracranial pressure (ICP) in mmHg in Group 2 in comparison with Group 1: from hour 18 till hour 168 of this study in the Neurosurgical ICU.
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Table 3 Glasgow Coma score and Noradrenalin infusion dose of the studied groups.
Group Time
6 h 12 h 18 h 24 h 30 h 36 h 42 h 48 h 54 h 60 h 66 h 72 h 78 h 84 h
Glasco Coma score
Group1 Mean
± SD
13.00
± .00
13.13
± .35
13.33
± .48
13.66
± .48
13.33
± .48
13.13
± .35
13.33
± .48
13.66
± .48
13.33
± .48
13.66±.48 13.13
± .35
13.33
± .48
14.13±.35 14.46
± .51
Group2 Mean
± SD
13.3333
± .48795
13.6667±.48795 14.0000±.00000 14.0000
± .00000
14.0000
±.00000
13.6667
± .48795
14.000
± 0 .00000
14.000
± 0 .00000
14.000
± 0 .00000
14.000
± 0 .00000
13.6667±.48795 14.000
± 0.00000
14.8667
± 14.8667
15.0000
± .00000
T test 2.64 3.43 5.29 2.64 5.29 3.43 5.29 2.64 5.29 2.64 3.43 5.29 5.70 4.00
P value \ \ \ \ \ \ \ \ \ \ \ \ \ \
Noradrenalin Inf. dose Inf..fdosedose
Group1 Mean
± SD
05
± .00
05
± 00
.05
± .00
.07
± .005
.07
± .005
.07
± .005
.07
± .005
.07
± .010
.07
± .010
.08
± .010
.08
± .010
.08
± .005
.08
± .005
.08
± .00
Group2 Mean
± SD
05
± 0.0
05
± 0.0
05
± 0.0
.08
± 0.01
.08
± 0.01
.08
± 0.01
.08
± 0.01
.08
± 0.01
.08
± 0.01
.09
± .005
.09
± .005
.09
± .005
.09
± .005
.09
± .005
T test .00 .00 .000 1.93 1.93 1.93 3.83 2.16 2.70 4.09 4.09 .00 .00 3.50
P value 1.000 1.000 1.000 .064 .064 .064 \ \ \ \ \ \ \ \
Time
90 h 96 h 102 h 108 h 114 h 120 h 126 h 132 h 138 h 144 h 150 h 156 h 162 h 168 h
Glasco Coma score
Group1 Mean
± SD
14.06±.25 14.06
± .25
14.13
± .35
14.13
± .35
14.06
± .25
14.13±.35 14.46
± .51
14.06±.25 14.46
± .51
14.46
± .51
14.46
± .51
14.46
± .51
14.46
± .51
14.46
± .51
Group2 Mean
± SD
14.4667±.51640 14.4667
± .51640
14.8667
± 14.8667
14.8667
± 14.8667
14.4667
± .51640
14.8667
± 14.8667
15.0000
± .00000
14.4667
±.51640
15.0000
± .00000
15.0000
± .00000
15.0000
± .00000
15.0000
± .00000
15.0000
± .00000
15.0000
± .00000
T test 2.68 2.68 5.70 5.70 2.68 5.70 4.00 2.68 4.00 4.00 4.00 4.00 4.00 4.00
P value \ \ \ \ \ \ \ \ \ \ \ \ \ \
Noradrenalin Inf. dose Inf..fdosedose
Group1 Mean
± SD
.08
± .004
.08
± .01
.08
± .01
.08
± .01
09
± .01
09
± .01
09
± .01
09
± .01
09
± .01
09
± .01
16
± .00
.16
± .00
16
± .005
17
± .21
Group2 Mean
± SD
.09
± .005
0.10
± .00
11
± .03
11
± .03
11
± .03
11
± .03
11
± .03
11
± .03
11
± .03
11
± .03
16
± .25
16
± .25
16
± .25
.18
± .29
T test .00 3.05 2.55 2.55 2.25 2.25 2.25 2.25 2.25 2.25 1.55 1.55 1.49 042
P value \ \ \ \ \ \ \ \ \ \ .130 .130 .145 .967
Signiﬁcant increase (\) in Glasgow Coma score in Group 2 in comparison with Group 1: from hour 6 till hour 168 of this study in the Neurosurgical ICU. Signiﬁcant increase (\) in Noradrenalin
Infusion dose (lg/kg/min) in Group 2 in comparison with Group 1: from hour 42 h 144 of this study in the Neurosurgical ICU.
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Table 4 Liver and kidney function of the studied groups.
Org. function Gr Day
1st 2nd 3rd 4th 5th 6th 7th
Serum ALT U/L Group 1 39.8 ± 1.8 41.7 ± 4.04 38.6 ± 1.5 37.93 ± 1.03 39.6 ± 1.5 43.13 ± 1.59 37.93 ± 1.03
Group 2 40.1 ± 1.5 41.4 ± 2.13 37.3 ± 2.41 38.6 ± 3.8 38.3 ± 2.41 40.6 ± 2.8 38.6 ± 3.8
T test 0.561 0.282 1.73 0.719 1.71 3.06 0.72
P value 0.579 0.78 0.14 0.478 0.1 \ 0.48
Serum AST U/L Group 1 20.5 ± 5.6 22.4 ± 5.34 21.0 ± 4.0 24.2 ± 6.1 22.53 ± 2.7 25.4 ± 4.9 24.07 ± 4.41
Group 2 21.4 ± 4.6 24.0 ± 5.74 23.06 ± 4.26 24 ± 4.7 23.6 ± 4.8 24.7 ± 5.4 24.3 ± 5.8
T test .465 .790 1.297 100 .751 .390 .141
P value 0.645 0.436 0.205 0.921 0.459 0.700 0.88
S. albumen g/L Group 1 30.66 ± 3.26 30.46 ± 3.13 30.73 ± 3.26 31.20 ± 3.80 32.20 ± 3.00 31.26 ± 2.49 32.06 ± 2.71
Group 2 30.26 ± 2.89 30.93 ± 3.88 31.60 ± 3.60 33.20 ± 2.78 31.80 ± 2.27 30.60 ± 3.92 31.73 ± 2.84
T test .355 .362 .691 1.644 .411 .555 .329
P value .725 .720 .495 .111 .684 .583 .745
S. bilirubin lmol/L Group 1 6.73 ± 1.75 5.73 ± 2.18 4.46 ± 2.13 6.33 ± 1.63 5.86 ± 1.92 4.60 ± 2.09 4.46 ± 2.13
Group 2 5.86 ± 2.44 5.13 ± 2.19 5.78 ± 2.45 5.21 ± 2.22 4.92 ± 1.89 4.85 ± 1.79 3.85 ± 1.65
T test 1.116 .749 1.547 1.552 1.321 .354 .855
P value .274 .460 .133 .132 .198 .726 .400
Serum urea Mmol/L Group 1 4.7 ± 0.3 4.4 ± 0 .4 4.53 ± 0.5 4.0 ± 0.4 4.5 ± 0.5 4.7 ± 0.3 4.8 ± 0 .4
Group 2 4.7 ± 0.3 4.2 ± 0.3 4.62 ± 0 .4 4.4 ± 0.6 4.6 ± 0 .4 4.7 ± 0.3 4.8 ± .3
T test \ 0.83 .99 2.6 .99 \ \
P value 1.0 0.415 0.32 0.16 0.32 1.0 0.96
Serum Cr lmol/L Group 1 66.86 ± 5.19 66.80 ± 4.03 72.00 ± 6.95 76.06 ± 6.62 78.40 ± 6.98 78.73 ± 7.07 76.86 ± 8.07
Group 2 68.73 ± 5.83 69.73 ± 5.53 68.13 ± 6.47 71.93 ± 2.37 74.20 ± 6.58 80.80 ± 3.27 76.73 ± 8.19
T test .925 .363 1.575 2.274 1.695 1.026 1.026
P value 1.658 .108 .126 \ .101 .313 .317
No signiﬁcant changes between groups 1 and 2 as regard organ functions Serum (ALT, AST, albumen, bilirubin, Creatinine, and urea) during
the 7 days of the study.
Table 6 World Federation of Neurological Surgeons Grading
System for Subarachnoid Hemorrhage (WFNS) scale.
Grade Motor deﬁcit Glasgow Coma score
1 Absent 15
2 Absent 13–14
3 Present 13–14
4 Present or absent 7–12
5 Present or absent 3–6
Where a motor deﬁcit refers to a major focal deﬁcit interpretation:
 Maximum score of 15 has the best prognosis.
 Minimum score of 3 has the worst prognosis.
 Scores of 8 or above have a good chance for recovery.
 Scores of 3–5 are potentially fatal, especially if accompa-
nied by ﬁxed pupils.
Table 5 Age, gender, and body weight.
Patient data Group
Group 1 Group 2
Age (years) 41.44(14.3) 43.16(13.9)
Gender
(Male) 8 8
(Female) 7 7
Body weight (kg) 75.34(9.1) 78.65(7.4)
No signiﬁcant difference between the two groups as regard age,
gender and body weight; values are in mean and standard deviation
(SD).
80 M.A. Ghanem, A.M. Shabana(CBF) improving the global cerebral oxygenation. In line with
this result (Yoshiki and his colleagues 2004), [13] suggested
that Milirinone cerebral cisternal irrigation has an effective
cerebral arterial VD effect is sufﬁcient enough to reduce the
occurrence of vasospasm in patients with poor grade aneuris-
mal SAH. Also, in accordance to our result, (Shankar and
his colleagues 2011) [14] documented that milirinone intra-
arterial infusion increased the cerebral blood ﬂow via reversing
the arterial spasm. Thereafter, Milrinone can improve the glo-
bal cerebral oxygenation during the serious period of post-
cerebral aneurismal clipping in the ICU.As regard to the Milrinone cardiac +ve inotropic mecha-
nism (Alousi and his colleagues 1986) [15] suggested that Milri-
nonemay stimulate the inﬂux of Ca++ into the cardiac cell. As
phosphodiesterase inhibitor that increase cardiac cAMP levels.
However, analyzing a time-course of the changes in cAMP levels
during the inotropic response to bipyridines indicated that the
isometric tension elevation development preceded the increase
in cAMP level. Lastly, Alousi concluded that more than one
mechanism may be involved in the initiation and maintenance
of the inotropic response to the Milrinone.
Effects of Milrinone continuous intravenous infusion on global cerebral oxygenation and cerebral vasospasm 81A co-link in our results between invasive Mean Arterial
Blood Pressure and norepinephrine infusion dose documented
as signiﬁcant increase in invasive Mean Arterial Blood Pres-
sure in Group 2 in comparison with Group 1 from hour 6 till
hour 168 of this study as shown in Table 1 associated with in-
creased IV infusion dose of norepinephrine in group 2 in com-
parison with group 1 from hour 42 till hour 144 of this study
Table 3, this can be explained by the combined effects of the
potent VC effect of norepinephrine in addition to the +ve ino-
tropic effect of Milrinone. Considering the infusion dose of
norepinephrine shown in Table 3 that we got most signiﬁcantly
increased IV infusion dose of norepinephrine in group 2 in
comparison with group 1 explained by the increased need in
group 2 to counteract the systemic peripheral VD effect of
the simultaneously IV infused Milrinone. In opposition to this
explanation, Liu and his colleagues 1997 [16] concluded that
the vasodilator effect of Milrinone is strong enough to abolish
the vasoconstrictor effect of norepinephrine and in the same
line (Jeon and his colleagues 2006) [17] used the same Milri-
none infusion dose of our study and found that vasopressin
is better than norepinephrine in counteracting the post-infu-
sion Milrinone hypotension, but we can argue that opposing
opinions by the signiﬁcant increase in the continuous IV infu-
sion dose of the supporting norepinephrine.
Value of including the 6 hourly recording of the Noradren-
aline infusion dosing was to detect if there is need to increase
the needed infusion dose after adding the peripheral VD Mil-
rinone in group 2 to counteract this milrinone VD effect on the
IMAP and in turn on the CPP.
As regard Calculated CPP and ICP shown in Table 2: in this
present study, CPP was calculated from the famous formula
CPP =MBP-ICP Table 2 showed signiﬁcant increase in CPP
in Group 2 in comparison with Group 1 from hour 6 till hour
168 of this study, also Table 2 showed signiﬁcant increase in
ICP in Group 2 in comparison with Group 1 from hour 18 till
hour 168. These co-linked two results are dependent on each
other and can not be explained separately and can be explained
by the combined effects of the potent VC effect of norepineph-
rine in addition to the+ve inotropic effect ofMilrinone have in-
creased the MBP and subsequently increased the CPP, and ICP
(within the normal range) in group (2) compared to group (1). In
opposition to this explanation, (Fraticelli and his colleagues
2008) [12] studied twenty-two consecutive patients with angio-
graphically provenCVS (arterial diameter reduction>40%) in-
tra-arterial Milrinone was infused in the cerebral territory
involved and followed by continuous intravenous infusion until
day 14 after initial bleeding and recorded improving cerebral tis-
sue perfusion independently of mean arterial pressure.
As regard Glasgow Coma score (GCS) shown in Table 3:
shows signiﬁcant increase in Group 2 in comparison with
Group 1 from hour 6 till hour 168. The GCS was recorded
starting from the 1st hour after surgical clipping, and accord-
ing to this present study rules, it was decided for all cases of
both groups to be fully conscious and of GCS >12 in order
to detect any deterioration of conscious level with all signs
of newly developing cerebral spasm. The signiﬁcantly in-
creased GCS in group 2 in comparison with group 1 can be ex-
plained by the increased cerebral arterial vasodilator
Milrinone effect added to that milrinone +ve inotropic effect
augmented by the effective supporting systemic arterial vaso-
constrictor vasopressor effect of the norepinephrine maintain-
ing increased effective MABP&CBF enriching the vasodilatedcerebral arterial tree with effective CPP and CBF enough to
maintain effective brain perfusion, and also conscious level
seen as a mirror image for cerebral oxygenation shown in
the signiﬁcantly increased noninvasive cerebral O2 saturation
in (norepinephrine plus Milrinone group 2) than (norepineph-
rine alone group 1).
According to organ functions shown in Table 4, no signif-
icant changes between both groups 1 and 2 as regard Serum
ALT, serum AST, Serum bilirubin, Serum albumen, Serum
Cr, and serum urea during the 7 days of the study. All re-
corded organ function were routinely done as a guard against
any organ blood perfusion deterioration can happen with the
continuous IV infusion of VC norepinephrine (i.e., renal artery
spasm) putting in mind the fact that autoregulation is essen-
tially maintained independent of nervous and humeral stimuli
documented by (Kiil and his colleagues 1969) [18] who infused
norepinephrine continuously into the renal artery. In line with
our result (Anderson and his colleagues 1981) [19] who infused
norepinephrine intravenously at 0.2–0.4 lg/kg/min in con-
scious dogs, did not decreased the renal function even found
renal vasodilatation that could be attributed to the increase
in systemic blood pressure which in turn decreases renal sym-
pathetic tone. In opposition to this result, the old theory that
norepinephrine infusions have been reported to decrease
splanchnic and renal blood ﬂow, under normal circulatory
conditions, as well as during essential hypertension and hypo-
volemic hypotension. These reports have signiﬁcantly inhibited
the clinical use of norepinephrine, but if it is used to support a
vasodilated circulation with a normal or increased cardiac out-
put, it is likely to be the kidney’s friend not its foe [20].
Arterial Spasm accidents in each group were recorded as
follows: 3 cases of 15 = (20%) cases in group 2 (Norepineph-
rine plus Milrinone group) compared to 7 cases of
15 = (46.6%) cases in group 1(Norepinephrine alone group)
indicating signiﬁcant decrease in the occurrence of spasm dur-
ing continuous IV infusion of Milrinone with norepinephrine
than norepinephrine alone that can be explained by the contin-
uous effective cerebral arterial VD effect of the continuous IV
infusion of Milrinone and its +ve inotropic effect added to the
effective vasoconstrictor norepinephrine augmenting effect on
MABP which in turn increased the CPP and CBF, all these ef-
fects are very important factor in preventing the occurrence of
cerebral arterial spasm during the period of highest incidence
of cerebral vasospasm after cerebral aneurismal clipping. In
line with this result, Khajavi and his colleagues (1997) [21]
proved that experimental chronic cerebral vasospasm in canine
model can be prevented by intracisternal Milrinone injection
with no signiﬁcant changes in systemic hemodynamic, and
4 years later, Arakawa and his colleagues (2001) [3]’s study
suggests that cisternal irrigation with Milrinone is safe and
effective and reduces the occurrence of vasospasm in patients
aneurismal SAH. Very few or even nil number of studies were
done on the effect of intravenous infusion of Milrinone on pre-
venting post-aneurysmal clipping cerebral arterial spasm for
example; Fraticelli and his colleagues (2008) [12] mixed local
intra-arterial Milrinone infusion in the affected cerebral terri-
tory, then followed by continuous intravenous infusion until
day 14 after 1st bleeding, and concluded that Milrinone is safe
and effective for reversal of CVS after aneurismal SAH and
should be examined in a large randomized trial.
In conclusion, Milrinone continuous intravenous infusion
improved signiﬁcantly the global cerebral oxygenation and re-
82 M.A. Ghanem, A.M. Shabanaduced the incidence of cerebral vasospasm during the dangerous
period of cerebral spasm after cerebral aneurysm clipping sur-
gery in the neurosurgical ICU.Conﬂicts of interest
None.References
[1] James K, Liu, William T, Could well. Intra-arterial papaverine
infusions for the treatment of cerebral vasospasm induced by
aneurismal subarachnoid hemorrhage. Neurocrit Care
2005;2:124–32.
[2] Wilkins RH. Cerebral vasospasm. Crit Rev Neurobiol
1990;6:51–77.
[3] Arakawa Y, Kikuta K, Hojo M, et al. Milrinone for the
treatment of cerebral vasospasm after subarachnoid
hemorrhage: report of seven cases. Neurosurgery
2001;48(4):723–8.
[4] Constantoyannis C, Sakellaropoulos GC, Kagadis GC, et al.
Transcranial cerebral oxymetry and transcranial doppler
sonography in patients with ruptured cerebral aneurysms and
delayed cerebral vasospasm. Med Sci Monit 2007;10:35–40.
[5] Baumann Antoine, Derelle Anne-Laure, Mertes Paul-Michel,
et al. Seeking new approaches: milrinone in the treatment of
cerebral vasospasm. Neurocrit Care 2012;16:351–3.
[6] Hoefnagel D, Dammers R, Ter Laak-Poort MP, et al. Risk
factors for infections related to external ventricular drainage.
Acta Neurochirurg 2008;150(3):209–14.
[7] Steiner, Luzius A, Czosnyka. Continuous monitoring of
cerebrovascular pressure reactivity allows determination of
optimal cerebral perfusion pressure in patients with traumatic
brain injury. J Crit Care Med 2002;30(4):733–8.
[8] Mayer SA, Bernardini GL, Solomon RA. Subarachnoid
hemorrhage. In: Rowland LP, editor. Merritt’s
neurology. Philadelphia: Lippincott Williams and Wilkins;
2005. p. 28–338.
[9] Monique Pharm D BCPS Richer, Sylvie MSc Pharm D Robert,
Marcel MD FRCP Lebel. Renal hemodynamics during
norepinephrine and low-dose dopamine infusions in man. Crit
Care Med 1996;24(7):1150–6.
[10] Ruengsakulrach Permyos, MarkBrooks, David L, Hare, et al.
Preoperative assessment of hand circulation by means ofDoppler ultrasonography and the modiﬁed Allen test. J
Thorac Cardiovasc Surg 2001;121:526–31.
[11] David P, Adelson MD. Cerebral oximetry in the head-injured
patient: is it time for widespread application? Clin Neurosurg
2007;54:58–63.
[12] Fraticelli AT, Cholley BP, Losser MR, et al. Milrinone for the
treatment of cerebral vasospasm after aneurysmal subarachnoid
hemorrhage. Stroke 2008;39(3):893–8.
[13] Arakawa Yoshiki, Kikuta Ken-ichiro, Hojo Masato, et al.
Milrinone reduces cerebral vasospasm after subarachnoid
hemorrhage of WFNS grade IV or V. Neurol Med-Chirurg
2004;44(8):393–401.
[14] Shankar JJ, dos Santos MP, Deus-Silva L, et al. Angiographic
evaluation of the effect of intra-arterial milrinone therapy in
patients with vasospasm from aneurismal subarachnoid
hemorrhage. Neuroradiology 2011;53(2):123–8.
[15] Alousi AA, Johnson DC. Pharmacology of the bipyridines:
Amrinone and Milrinone. Circulation 1986;73(3 Pt 2), III10-24.
[16] Liu JJ, Doolan LA, Xie B, et al. Direct vasodilator effect of
milrinone, an inotropic drug, on arterial coronary bypass grafts.
FANZCA. J Thorac Cardiovasc Surg 1997;113(1):108–13.
[17] Jeon Y, Ryu JH, Lim YJ, et al. Comparative hemodynamic
effects of vasopressin and Norepinephrine after Milrinone-
induced hypotension in off-pump coronary artery bypass
surgical patients. Eur J Cardiothorac Surg 2006;29(6):952–6.
[18] Kiil F, Kjekshus J, Loyning E. Renal autoregulation during
infusion of Noradrenalin. Angiotensin Acetyl Acta Physiol
Scand 1969;76(1–2):10–23.
[19] Anderson WP, Korner PI, Selig SE. Mechanisms involved in the
renal responses to intravenous and renal artery infusions of
noradrenaline in conscious dogs. J Physiol 1981;321:21–30.
[20] Bellomo Rinaldo, Di Giantomasso David. Noradrenalin and the
kidney: friends or foes? Crit Care 2001;5:294–8.
[21] Khajavi, Kaveh MD, Ayzman, et al. Prevention of chronic
cerebral vasospasm in dogs with milrinone. Neurosurgery
1997;40(2):354–63.
[22] Teasdale G, Drake C, Hunt W, et al. A universal subarachnoid
hemorrhage scale: report of a committee of the World federation
of neurosurgical Societies. J Neurol, Neurosurg, Psychiat
1988;51(11):1457.
[23] Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal
and ventricular blood on risk of delayed cerebral ischemia after
subarachnoid hemorrhage: the Fisher scale revisited. Stroke
2001;32(9):2012–20.
